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Abstract
Background: Histopathological assessment has a low potential to predict clinical outcome in patients with the
same stage of colorectal cancer. More specific and sensitive biomarkers to determine patients’ survival are needed.
We aimed to determine gene expression signatures as reliable prognostic marker that could predict survival of
colorectal cancer patients with Dukes’ B and C.
Methods: We examined microarray gene expression profiles of 78 archived tissues of patients with Dukes’ B and
C using the Illumina DASL assay. The gene expression data were analyzed using the GeneSpring software and R
programming.
Results: The outliers were detected and replaced with randomly chosen genes from the 90 % confidence interval
of the robust mean for each group. We performed three statistical methods (SAM, LIMMA and t-test) to identify
significant genes. There were 19 significant common genes identified from microarray data that have been
permutated 100 times namely NOTCH2, ITPRIP, FRMD6, GFRA4, OSBPL9, CPXCR1, SORCS2, PDC, C12orf66, SLC38A9,
OR10H5, TRIP13, MRPL52, DUSP21, BRCA1, ELTD1, SPG7, LASS6 and DUOX2. This 19-gene signature was able to
significantly predict the survival of patients with colorectal cancer compared to the conventional Dukes’ classification
in both training and test sets (p < 0.05). The performance of this signature was further validated as a significant
independent predictor of survival using patient cohorts from Australia (n = 185), USA (n = 114), Denmark (n = 37) and
Norway (n = 95) (p < 0.05). Validation using quantitative PCR confirmed similar expression pattern for the six selected
genes.
Conclusion: Profiling of these 19 genes may provide a more accurate method to predict survival of patients with
colorectal cancer and assist in identifying patients who require more intensive treatment.
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Background
Colorectal cancer is one of the major causes of cancer
mortality in both sexes worldwide. The reported number
of CRC patients has increased to 1.4 million and associ-
ated with 694 000 deaths globally in 2012 [1]. CRC is
staged according to the extent whether it has spread
through the wall of colon and rectum or to other parts
of the body [2]. The prognosis is influenced by the stage
of CRC at the time of diagnosis [3]. Based on the
National Cancer Institute's Physician Data Query system,
the 5-year survival rate for Dukes’ A patients was 80 to
95 %, Dukes’ B 55 to 80 %, Dukes’ C 33 to 55 % and
Dukes’ D less than 15 % [4]. These data showed the cor-
relation between survival and staging where the higher
stage of CRC patients is associated with a lower survival
rate. However, a previous study reported that the sur-
vival rate of Dukes’ B patients with high risk pathological
factors or low nodes involvement was lower than Dukes’
C patients who had one positive node [3]. Thus, the
current staging method needs to be improved to provide
a more accurate prognostication for CRC patients. The
common practice in managing Dukes’ B patients is a
combination of surgery, chemotherapy and/or radiation
therapy [5]. Whether this should be applied for all cases
is still debatable [3]. The adjuvant chemotherapy may
benefit the Dukes’ B patients with high risk features but
this is still not routinely recommended. This is due to
less benefit obtained from the adjuvant chemotherapy as
10-20 % of patients will develop recurrence [6]. For
Dukes’ C patients, the adjuvant chemotherapy became a
standard treatment after showing a 40 % reduction of
recurrence rate [7]. Another study in 2004 has demon-
strated that the overall 5-year survival rate was poor in
patients with Stage IIb compared to those with stage IIIa
[4]. However, this result may be due to the misclassifica-
tion of staging which leads to poor survival in untreated
patients with micrometastasis [4]. Clearly, there are
pitfalls in using the current staging system for prognosti-
cation purposes.
Nowadays, the development of high throughput tech-
nologies such as RNA sequencing [8, 9] and microarray
[10, 11] become popular to generate gene expression
profiling in understanding of cancer. Microarray tech-
nology is still valuable and promising technology for
many years as it is more affordable compared to the
RNA sequencing. Eschrich et al. (2005) used cancer
tissues from patients with Dukes’ B, C and D, who have
been follow-up for at least 36 months. They found a
43-gene signature that categorize patients into good and
poor survival with 93 % sensitivity and 84 % specificity
[12]. But, a large scale validation could not be performed
due to the limitation to make decision for adjuvant treat-
ments [11, 13]. Several studies that analyzed patients
with Stage II and III CRC have developed molecular
classifiers that could stratify patients into high and low-
risk groups [14–16]. However, these studies are still in
the research phase were not been translated into clinical
practice [17]. Furthermore, some studies have used a
small number of samples and lack of validation in inde-
pendent samples to enhance the power of the gene
signatures [18]. Our aim for this study was to determine
gene expression signatures that could predict survival of
CRC patients with Dukes’ B and C CRC, hoping that a
set of gene signatures will be able to classify patients




This is a retrospective study using 78 formalin-fixed par-
affin embedded (FFPE) tissues of patients with Dukes’ B
(n = 37) and Dukes’ C (n = 41) CRC patients diag-
nosed between January 2002 to December 2007 at the
Universiti Kebangsaan Malaysia Medical Centre. These
samples comprised of patients who survived less than five
years (denoted as the poor survival group) and patients
who survived more than five years (good survival group).
The samples were anonymised throughout this study.
Inclusion criteria included the absence of preoperative
chemotherapy or radiotherapy. Information about age,
gender, race, histology, family history, organ sites and
clinical outcomes were recorded. For each patient, their
medical records and follow-up data were carefully
reviewed to confirm their clinical outcomes and the cause
of death if the patients were deceased. The survival of
patients was calculated from December 2012 minus the
date of the first surgery for those still alive while for those
who did not survive, it included the date of death minus
the date of the first surgery.
RNA extraction
Tissue sections of 4-7 μm in thickness were prepared
(>80 % representative), stained with hematoxylin and
eosin (H&E) and evaluated by the pathologist in charge.
RNA was deparaffinized and extracted using High Pure
RNA Paraffin Kit (Roche Applied Science, Mannheim,
Germany). Proteinase K was added and homogenization
was performed for16 h. All steps followed the manufac-
turer’s protocol. Samples were then stored at –80 °C
until they were used. Quantity and purity of the total
RNA was determined by the NanoDrop ND-1000 spec-
trophotometer (Thermo Fisher Scientific, Waltham,
MA). Samples with purity between 1.8 to 2.0 (A260/
A280) were selected. Quality assessment of total RNA
was done using the Bioanalyzer 2100 RNA 6000 Nano
kit (Agilent Technologies, Inc., CA, USA) and samples
with RNA Integrity Number (RIN) of more than two
were selected for the quantitative PCR.
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cDNA mediated annealing, selection, extension and
ligation (DASL) assay
Quantitative PCR analysis was performed as the pre-
qualifying step prior to cDNA synthesis using the
Corbett Rotor-Gene 6000 thermal cycler (Corbett Life
Science, Sydney, Australia). Forward and reverse primers
for the housekeeping gene RPL13A were obtained from
AITbiotech Singapore. PCR amplification with CT value
of 29 cycles or less was used in DASL assay (Illumina,
San Diego, CA, USA). The assay was conducted accord-
ing to the manufacturer’s protocol. Raw data files (.idat
files) were analyzed using the GenomeStudio software
(Illumina, San Diego, CA, USA) to check the data qual-
ity control for assessing results of gene expression
microarray experiment.
Microarray analysis
Sample Probe Profile from the GenomeStudio was
imported to the third party software called Genespring
GX 12.0.2 (Agilent Technologies, Inc., CA, USA).
Seventy-eight samples were exploitable with 20793
entities. The data were normalized using quantile al-
gorithm and log-transformed. Baseline transformation
of the normalized signal was performed to the me-
dian of all samples. Samples were assigned into their
survival groups. Hierarchical clustering was per-
formed using Pearson's correlation coefficient and Ward’s
criterion.
Outlier diagnosis for microarray analysis
It is well known that microarray gene-expression data
are often contaminated by outliers due to many steps in-
volved in the experimental process from hybridization
to image analysis [19, 20]. Most of the popular algo-
rithms for microarray gene-expression data analysis
are very much sensitive to outliers [19]. So gene-
expression data analysis by these algorithms may pro-
duce misleading results in the presence of contami-
nated observations.
We identified the contaminated observations for
each gene using β-weight function [21, 22] and re-
placed them with the values belonging to the 90 %
robust confidence interval (rCI) of the respective
group mean. The 90 % rCI for the j-th group mean
(μi
(j)) of i-th gene is defined by
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i;β are the minimum β-divergence esti-
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, xik
(j) is the k-th expression in
group-j of gene-i, i = 1,2,….,N = 20793; j = 1,2; n1 + n2 = 78,























as β-weight function that we used for outlier detection as
mentioned earlier. This weight function produces weights
between 0 and 1 for any observation detected. It produces
smaller weights only for contaminated observations. So, in
this study we consider an observation (xik








and replaced it with a value belonging to the 90 %
rCI of mean μ jð Þ
i
 
as the defined eq. (1). The β-
estimators as defined in eqs. 2 and 3 are highly ro-
bust against outliers [21, 22].
Detection of differentially expressed (DE) gene
We permutated 100 times from one data the microarray data
obtained from78 patients. All patients were divided into two
subsets of equal numbers i.e., training and test sets. We used
the bootstrapped data with three statistical methods (SAM,
LIMMA and t-test) to each training and test set to detect sig-
nificantly DE genes between good and poor survival group.
Survival analysis
Cox proportional hazards model and Elastic net estimation
To estimate the relationship between the survival time
and the gene expression levels, we used n as a sample of
n size and X1, . . .,Xp of p genes to denote the gene
expression level. The survival data for the ith patient
denoted by (Ti, δi, xi1, xi2, . . . xip), where i = 1, 2, . . ., n,Ti
is the survival time of i patient, δi is censoring
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indicator (0 if alive, 1 death) and xi = {xi1, xi2, . . ., xip} is
the vector of the gene expression level of p genes (covari-
ates). We also used the Cox regression model for the
hazard of CRC death at time t which is defined by
λ tð Þ ¼ λo tð Þ exp β1X1 þ β2X2 þ ⋅⋅⋅þ βpXp
 
¼ λ0 tð Þ exp βTX
 	
;
where λ0(t) is an unspecified baseline hazard function,
β = {β1, β2, · · ·,βp} is the vector of regression coeffi-
cients and X = {X1, . . .,Xp} is the vector of gene ex-
pression levels with the corresponding sample values
of xi = {xi1, . . ., xip} for the ith sample. The the risk
score of patient was calculated from the function:
Risk Score ¼ f Xð Þ ¼ βTX ð5Þ
Based on the available sample data, the Cox’s partial
likelihood can be written as











where D is the set of indices of the events (e.g., deaths)
and Rr denotes the set of indices of the individuals at
risk at time tr − 0. The Elastic Net [23] uses a mixture of
the L1 (lasso) and L2 (ridge regression) penalties. In the
Elastic Net, the usual partial log-likelihood is penalized
by the L1 and L2 norms of the regression coefficients
with weights λ1 and λ2, respectively, i.e.,:










where λ1 and λ2 are tuned by maximizing l(β), and l(β) is
the cross-validated partial log-likelihood (CVL). LASSO
and Ridge regression are described by Eq. (2) with λ1 or λ2
non-zero, respectively. The λ1 + λ2 Elastic Net involves 2D
optimization of the penalties. The penalty parameters were
tuned 50 times using different folding of the data for calcu-
lating CVL, and the penalty parameters with maximum
CVL were selected by pensim R package, available at
http://cran.r-project.org/web/packages/pensim/index.html.
We performed the Elastic Net [23] using the opt2D
function of the “pensim” R package to predict the survival
of CRC patients from microarray data. Using a 10-fold
cross-validation, with 50 starts parallelized to 8 processors
using the opt2D function, we obtained regression coeffi-
cients (β) with the optimal penalty parameter for the pe-
nalized Cox model, and calculated the risk score for each
patient using eq. (5) where βi is the estimated regression
coefficient of each gene in the training data set and Xi is
the Z-transformed expression value of each gene. The
estimated regression coefficient of each survival related
gene given by Elastic Net in eq. (6) in the training data set
was also applied to calculate a risk score for each patient
in test data set. The linear risk score with greatest cross-
validated partial log-likelihood was selected for validation
in the test set. We classified all patients into the 2 groups
high and low risk groups using the cut-off value (median
risk score) in the training set. Patients were assigned to
the "high-risk" group if their risk score was more than or
equal to cut-off value of risk score, whereas those with less
than the cutoff values were assigned as "low-risk". The
patients in high-risk group are expected to have a poor
outcome. The statistical significance of the predictions
was then assessed by the likelihood ratio test on the Cox
proportional hazards model. The probe sets were scaled
to z-scores per feature for all datasets. An individual
patient (test patient) can be checked to predict whether
the patient should receive further treatment or no treat-
ment by the fitted risk score (eq. 5), where X = {X1, . . .,Xp}
takes the expression values of selected p = 19 genes from
the test patient in the real life daily practice.
The values of specificity and sensitivity of the 19-genes
was calculated based on the analysis of gene expression
from this study as compared to the selected genes from
other publications [14, 15].
Independent external validation
We compared our microarray data with the published
datasets obtained from Stage II and III CRC patients
from four separate international studies (Australia, USA,
Denmark and Norway) [11, 14, 15, 24]. The datasets
were accessed online from Gene Expression Omnibus
(GEO) (GSE14333, GSE17536/GSE17537, GSE31595 and
GSE30378). The platform used was Affymetrix HG-U133
Plus2.0. The raw fluorescence intensity data within CEL
files were pre-processed with Robust Multichip Average
(RMA) algorithm [8], as implemented with R packages
from Bioconductor (http://www.bioconductor.org), and
the data were log-transformed. Clinical information of the
publicly available microarray data sets was obtained from
the published articles and websites. In addition, the data
were normalized per gene in each data set by transforming
the expression of each gene to obtain a mean of 0 and SD
of 1 (Z-transformation) for this study.
Validation using quantitative PCR (qPCR)
Six genes (FRMD6, SLC38A9, TRIP13, MRPL52, ELTD1
and ITPRIP) were randomly selected for the validation
of the microarray data. Results were normalized with
RPL13A gene. The extracted total RNA was converted
to cDNA using Verso cDNA Synthesis kit (Thermo
Scientific, UK). For qPCR, 25 μl reactions were set up
using 12.5 μl of 2X Solaris qPCR Master Mix, 1.25 μl of
Solaris Primer/Probe Set (20X), 1 μl of cDNA template
and water to make up to total volume 25 μl. The qPCR
reactions were performed using the Rotor-Gene 6000
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thermal cycler (Corbett Life Science). Cycling program
involved one cycle of enzyme activation at 95 °C for
15 min, 40 cycles consist of denaturation at 95 °C for
15 s and annealing/extension at 60 °C for 60 s.
Results
Clinical and pathological features
Clinical and pathological features of 78 patients were
separated into poor and good survival groups of patients
who survived less than five years and more than five
years respectively. In this study, the 5 year survival rate
among patients of Dukes’ B was 59.5 % while Dukes’ C
was 36.5 %. It was in concordance to the United State
data [4]. The differences in clinical parameters between
Dukes’ B and C patients were not statistically significant
(Fisher’s exact test p = 0.173) (Table 1). Kaplan Meier
curves were constructed based on Dukes’ staging and
the survival time showed no statistically significant
difference (log rank p = 0.242, data not shown). Fig. 1
showed the H&E staining results of patient Dukes’ B and C.
Identification of DE genes between good and poor
survival groups
Based on the eqs. (4 & 4.1), we identified 7.7 % of 20793
probes as contaminated probes (Additional file 1). Then,
we updated all contaminated expressions for each gene
using the reasonable values belonging to the 90 % rCI of
their respective group means as discussed earlier.
Thus, a total of 1500 top-ranked DE genes (using
smaller adjusted p-values) was selected from each of
training and test datasets by each of three statistical tests
(See Methods). Overlapping genes obtained by three
statistical test were again overlapped between each of
the training and test datasets (Additional file 1). Finally
we obtained 19 significant DE genes (NOTCH2, ITPRIP,
FRMD6, GFRA4, OSBPL9, CPXCR1, SORCS2, PDC,
C12orf66, SLC38A9, OR10H5, TRIP13, MRPL52, DUSP21,
BRCA1, ELTD1, SPG7, LASS6 and DUOX) for further
investigation (Table 2).
Figure 2 shows an example of the hierarchical cluster-
ing of microarray results based on 19 DE genes from a
pair of training set 1 and test set 1.
Predicting survival of cancer patients from CRC gene
expression data
We performed the Elastic Net [23] to the training
dataset and compute the risk scores using eq. (5)
based on the model estimates to the training dataset
and the test dataset. After calculating the risk score
for each patient from the 19-gene expression signa-
ture as mentioned before, we divided the training set
into high and low risk groups based on the cutoff
value (-0.07) of the risk score. The likelihood ratio
test was used to compare differences in overall survival
between high and low risk groups in the training set 1
(likelihood ratio test, p <0.05; HR =27, (95 % CI, 5.165 –
140.5)) and test set 1 (likelihood ratio test, p <0.05,
HR = 12, (95 % CI, 2.861 – 47.21)). Both Kaplan
Meier survival plots (Fig. 3a and b) for training and
test set 1 showed that this risk classification was sig-
nificantly associated with the overall survival time.
Similar results were observed in the other training
and test sets. We also compared other two methods
such as LASSO and Ridge regression with Elastic Net
regression for prediction accuracy in our data. The
prognostic index (risk score of 19 gene signature) was
significantly associated with overall survival time in
multivariate analysis (Table 3).
This study showed that the sensitivity and specifi-
city of the 19-genes were 86.84 % and 87.50 % re-
spectively which were acceptably higher than the
ColoGuideEx with 72.22 % and 71.43 % respectively
for 13-genes signature [14]. Meanwhile, ColoGuidePro
[15] has the upmost value of analysis with 94.44 %
and 90.48 % for 7-genes respectively. To identify
genes that may predict overall survival, a univariate
Cox proportion hazard regression analysis was per-
formed with each of 19 differentially expressed genes
in CRC in a cohort of 78 patients (Table 4). Table 4





No (%) No (%) p value
Dukes’ B 22 (56.41) 15 (38.46) 0.173 **
C 17 (43.59) 24 (61.54)
Gender Male 20 (51.28) 20 (51.28) 1.000 **
Female 19 (48.72) 19 (48.72)
Age (year) ≤50 4 (10.26) 5 (12.82) 0.235 **
>50 35 (89.74) 34 (87.18)
Race Chinese 29 (74.36) 24 (61.54) 0.226 *
Malay 9 (23.08) 15 (38.46)
Indian 1 (2.56) 0
Tumor differentiation Well 26 (66.67) 15 (38.46) 0.051 *
Moderately 5 (12.82) 15 (38.46)
Poorly 1 (2.56) 2 (5.13)
Mucinous 2 (5.13) 4 (10.26)
No record 5 (12.82) 3 (7.69)
Clinical outcome Alive 34 (87.18) 0 0.000 **
Dead 5 (12.82) 39 (100.00)
Organ Colon 25 (64.10) 21 (53.85) 0.357 **
Rectum 14 (35.90) 18 (46.15)
* = p value was calculated using Pearson Chi-Square
** = p value was calculated using Fisher’s Exact Test
[Relevant location: Page 13]
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shows that most of the genes including validated 5 genes
(FRMD6, MRPL52, TRIP13, ELTD1 and SLC38A9) were
significantly correlated with the overall survival of the
CRC patients. The five validated genes were significantly
correlated with the overall survival with hazard ratios of
1.259 [p =0.001; 95 % confidence interval (CI): 1.092 to
1.452], 0.848 (p = 0.001; 95 % CI: 0.767 to 0.939),
0.881 (p = 0.008; 95 % CI: 0.802 to 0.968), 1.155 (p = 0.021;
95 % CI): 1.021 to 1.307) and 0.919 (P = 0.050; 95 % CI:
0.845 to 1) respectively.
To determine whether these 19 genes can be inde-
pendent prognostic markers, multivariate analysis was
also performed including other clinical parameters (age,
gender and stage) as shown in Table 4. The results
showed that five genes (NOTCH2, GFRA4, OSBPL9,
MRPL52 and LASS6) as independent predictors with
hazard ratios of 1.56 (P = 0.009, 95 % CI: 1.034 to
1.913), 0.871 (p = 0.010, 95 % CI: 0.547 to 1.005), 0.818
(p = 0.047, 95 % CI: 0.640 to 1.045), 0.865 (p = 0.019,
95 % CI: 0.697 to 1.075) and 0.788 (P = 0.035, 95 % CI:
Fig. 1 a Cancerous tissue section of patients Dukes' B well-differentiated adenocarcinoma. Hematoxylin (purple) stains chromatin in the nucleus
and eosin (pink orangish) gives color to the protein that resides in the cytoplasm of muscle cells. Tumor cells appear to thicken and be seen
spreading muscular propia but did not penetrate serous layer. b. Well differentiated adenocarcinoma Dukes’ C tissue section invaded into muscular
propia and involved lymph nodes
Table 2 Microarray-based changes in gene expression of the 19 genes
Probe ID Gene symbol aFold change Gene name Expression in poor survival group
(Up-regulated/Down-regulated)
7000692 MRPL52 -4.32 (-2.59) mitochondrial ribosomal protein L52 Down-regulated
5700373 TRIP13 -3.49 (-3.22) thyroid hormone receptor interactor 13 Down-regulated
2690324 ITPRIP 1.36 (1.23) inositol 1,4,5-triphosphate receptor interacting protein Up-regulated
7000184 SLC38A9 -3.89 (-3.08) solute carrier family 38, member 9 Down-regulated
5420070 FRMD6 3.65 (2.63) FERM domain containing 6 Up-regulated
4230739 SORCS2 2.96 (3.58) sortilin-related VPS10 domain containing receptor 2 Up-regulated
6040070 ELTDI 3.68 (2.59) EGF, latrophilin and seven transmembrane domain containing 1 Up-regulated
1190176 NOTCH2 3.37 (2.62) Notch homolog 2 Up-regulated
2570196 CPXCR1 -2.62 (-2.18) CPX chromosome region, candidate 1 Down-regulated
840367 OR10H5 -2.20 (-1.93) olfactory receptor, family 10, subfamily H, member 5 Down-regulated
3450575 PDC -3.06 (-1.75) phosducin Down-regulated
2710564 DUOX2 2.22 (3.01) dual oxidase 2 Up-regulated
4560474 GFRA4 -2.91 (-1.63) GDNF family receptor alpha 4 Down-regulated
5690064 LASS6 -2.69 (-2.45) LAG1 homolog, ceramide synthase 6 Down-regulated
3780725 OSBPL9 -2.04 (-2.45) oxysterol binding protein-like 9 Down-regulated
5090025 C12orf66 -1.15 (-1.11) chromosome 12 open reading frame 66 Down-regulated
5870121 SPG7 3.64 (4.57) spastic paraplegia 7 (pure and complicated autosomal recessive) Up-regulated
620398 DUSP21 -3.53 (-2.92) dual specificity phosphatase 21 Down-regulated
540411 BRCA1 -3.88 (-3.07) breast cancer 1, early onset Down-regulated
This table shows the probe ID, gene symbols and expression of the 19 genes in the poor survival group compared to the good survival group. aFold change:
training set (test set)
[Relevant location: Page 13]
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0.631 to 0.984) respectively. To improve the prognostic
capability, a risk score was calculated based on the
expression level of NOTCH2, GFRA4, OSBPL9,
MRPL52 and LASS6 and corresponding regression
coefficients. A patient’s risk score was calculated as the
sum of the expression values of these genes. The results
confirmed that the patients in the low-risk score group
also had a better prognosis than those in the high-risk
score group in the test set. This data suggest that the
risk score based on these five genes can be used to
stratify patients (Fig. 3c).
Survival analysis of the 19-gene signature using the USA,
Australia, Denmark and Norway datasets
We assessed the predictive power of the 19 gene signa-
tures on the four cohort datasets from the USA (n =
114), Australia (n = 185), Denmark (n = 37) and Norway
(n = 95). All the microarray data were obtained using the
Affymetrix platform and we confirmed that the risk
classification using the 19 genes were replicated in all
three datasets. We found 17 out of 19 gene signatures
were present in the datasets from the USA, Australia
and Norway while 18 out of 19 genes were present in
the dataset from Denmark.
The Kaplan Meier survival curves for the high and low
risk score groups are shown in Fig. 3d-f. Patients with
high risk scores showed significantly poorer overall
survival than the patients with low risk scores for the
USA dataset (likelihood ratio test p-value <0.01; HR =
4.9 (95 % CI, 1.827 – 12.99)), for the Australian data-
set, (likelihood ratio test p-value <0.01; HR = 1.8
(95 % CI, 1.268 – 2.533)) and for the dataset from
Denmark (likelihood ratio test p-value <0.01; HR = 8.6
(95 % CI, 1.842 – 40.05)). Interestingly, we observed
that the median risk score for all external validation
datasets as well as our training dataset situated be-
tween -0.099 and -0.038. We again compared LASSO
and Ridge with Elastic Net regression for prediction
patients into high and low risk survival groups in
external datasets from different countries. The prog-
nostic index was significantly associated with overall
survival time in most of the external datasets in
multivariate analysis (Table 3). We observed that the
LASSO and Ridge methods fail to obtained prognostic
index to measure the association, while the elastic net
was significantly associated with overall survival time
in the Norway dataset (Table 3).
Validation of the microarray data
Validation using qPCR demonstrated similar trends
between poor and good survival groups when compared
with the microarray data. All up-regulated genes
(FRMD6, ELTD1 and ITPRIP) and down-regulated genes
(MRPL52, TRIP13 and SLC38A9) were confirmed by
qPCR according to 2-ΔΔCT method as seen in Fig. 4.
Fig. 2 Hierarchical clustering of gene expression datasets. Hierarchical clustering of 78 CRC samples in training and test sets which graphically
displays the intensity of the gene expression for each gene. Samples were clustered based on the 19 significant genes. The color of each square
boxes represents the ratio of gene expression. Red boxes indicates up regulated genes while green boxes represents down regulated genes.
The column represent individual tissue samples while rows represent individual of genes
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Fig. 3 Survival analysis. Kaplan–Meier survival analysis using six different microarray datasets (Training and test sets (Illumina-based), dataset from
Denmark (Affymetrix), dataset from the USA (Affymetrix) and dataset from Australia (Affymetrix)). The 19-gene signature segregates patients into
two risk groups (red, high risk; black, low risk). The p values correspond to the likelihood ratio test comparing the survival curves
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Discussion
Microarray profiling allows the analysis of thousands of
genes and the identification of differentially expressed
genes which could then be used to characterize colorec-
tal cancer from a molecular perspective. We performed
a microarray study using the DASL assay on CRC
patients with Dukes’ B and C to predict patient’s sur-
vival. This assay was designed with multiple probes per
transcript to generate reproducible gene expression pro-
files from partially degraded RNA in archival tissues
which had the advantage of information on the patients’
survival. The quality of microarray data for downstream
analysis is important in order to answer correctly the
research questions. Outlier detection in microarray data
is desirable to avoid noise and statistical damage with
the aim to minimize the risk of misinterpreting the bio-
logical events.
This study has successfully stratified colorectal cancer
using a 19-gene signature and provides a molecular
staging approach of patients into low risk and high risk
groups. The final aim is to use this identifier in a
personalized approach for CRC patients as there are
weaknesses in using histopathological examination alone
to prognosticate patients’ survival. The overall survival
rate for CRC patients has increased, however, the indi-
vidual survival rate for patients with Dukes’ B and C is
still low. A previous study developed a molecular classi-
fier based on a core set of 43 genes to predict the 3-year
survival for patients [12]. The gene signatures were also
validated on a different population using a different plat-
form. In this study, we identified gene signatures which
could predict the 5-year survival rate. This is important
to allow the best plan of treatment to be given to patients
while at the same time reducing unnecessary toxicity and
aggressive side effects.
The Oncotype Dx and Coloprint for colorectal cancers
are two different assays developed based on quantitative
multi-gene RT PCR assay and oligonucleotide micro-
array respectively. Both assays were developed to im-
prove risk stratification of relapse for patients with Stage
II CRC. Oncotype Dx has a limitation in which identified
genes were derived from four separate studies on
individual genes and not determined using the whole
genome microarray method. Therefore, the assay could
probably miss important genes that may be involved in
determining cancer relapse. Another disadvantage of the
assay is the difficulty in assigning patients into groups of
risk prediction due to the narrow range of prediction
scores. These challenges hinder the effective use of this
assay in clinical practice [25]. The gene expression data
from Coloprint was not made publicly available hence
the evaluation of the classifier cannot be performed [14].
A recent study developed 113 gene signatures from a
published gene expression profile to predict prognostic
risk [26]. Prognostic index for patients was calculated to
discriminate patients into high- and low risk group. To
show the prognostic significance, validation was done
using independent data sets from different countries
using the same platform. In this study, we completed the
whole genome microarray and calculated a risk score for
each patient. We used the median risk score as a cutoff
point in which the median was not affected by outliers
[27]. Using this median, the patients were efficiently
separated into two groups i.e., high and low risk groups.
Previous clinical trials have used two robust gene classi-
fiers called ColoGuide Ex and ColoGuide Pro. The investi-
gators used the classifiers to stratify the prognosis of
patients with stage II and III [14, 15]. The performances
of both classifiers were validated using independent
external datasets from different countries. The strength of
the classifier is that it requires validation at the individual
patient level conducted in the prospective trial. In our
study, we revealed a set of genes which could provide a
significant risk assessment approach for patients in both
intermediate stages (Dukes’ B and C). Therefore, an
Table 3 Univariate and multivariate cox proportional hazard
regression analyses
Genes Univariate Multivariate
Hazard ratio (95 % CI) p-value Hazard ratio (95 % CI) p-value
NOTCH2 1.356 (1.154 – 1.592) 0.000 *** 1.56 (1.034 – 1.913) 0.009 **
ITPRIP 1.063 (0.919 – 1.23) 0.408 0.852 (0.614 – 1.183) 0.340
FRMD6 1.259 (1.092 – 1.452) 0.001 ** 1.066 (0.850 – 1.338) 0.575
GFRA4 0.860 (0.728 – 1.016) 0.005 ** 0.871 (0.547 – 1.005) 0.010 **
OSBPL9 0.803 (0.671 – 0.962) 0.017 ** 0.818 (0.640 – 1.045) 0.047 **
CPXCR1 0.918 (0.811 – 1.041) 0.183’ 1.030 (0.766 – 1.387) 0.840
SORCS2 1.159 (1.041 – 1.290) 0.006 ** 0.936 (0.752 – 1.166) 0.558
PDC 0.812 (0.679 – 0.970) 0.022 ** 1.068 (0.796 – 1.432) 0.659
C12orf66 0.902 (0.808 – 1.008) 0.069 * 1.007 (0.729 – 1.390) 0.965
SLC38A9 0.919 (0.845 – 1.000) 0.050 * 1.073 (0.894 – 1.289) 0.443
OR10H5 0.846 (0.704 – 1.018) 0.075 * 1.078 (0.826 – 1.407) 0.579
TRIP13 0.881 (0.802 – 0.968) 0.008 ** 0.985 (0.780 – 1.244) 0.901
MRPL52 0.848 (0.767 – 0.939) 0.001 ** 0.865 (0.697 – 1.075) 0.019 **
DUSP21 0.903 (0.807 – 1.011) 0.077 * 0.928 (0.697 – 1.235) 0.609
BRCA1 0.836 (0.764 – 0.915) 0.000 *** 0.884 (0.713 – 1.097) 0.264
ELTD1 1.155 (1.021 – 1.307) 0.021 ** 0.969 (0.772 – 1.216) 0.787
SPG7 1.141 (1.035 – 1.259) 0.008 ** 1.026 (0.840 – 1.255) 0.797
LASS6 0.867 (0.782 – 0.961) 0.006 ** 0.788 (0.631 – 0.984) 0.035 **
DUOX2 1.076 (0.975 – 1.187) 0.141’ 1.039 (0.844 – 1.280) 0.715
Age (>60) 0.154 (0.01953 – 1.225) 0.045 ** 0.562 (0.0354 – 2.392) 0.049 **
Gender 1.048 (0.554 – 1.981) 0.886 1.729 (0.704 – 4.245) 0.231
Stage 1.644 (0.8567 – 3.156) 0.135’ 1.274 (0.494 – 3.286) 0.615
This table shows the univariate and multivariate cox proportional hazard
regression analyses of 19 gene signatures and other clinical variables
associated with overall survival of CRC patients. [Relevant location: Page 14]
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Table 4 Comparison the LASSO and Ridge regression methods with Elastic Net regression
Univariate Multivariate
HR (95 % CI) P HR (95 % CI) P
Datasets Methods
Lasso 0.106 (0.030 – 0.370) 0.000 0.063 (0.016 – 0.252) 0.000
Our dataset Ridge 0.812 (0.303 – 2.173) 0.000 0.083 (0.022 – 0.321) 0.000
Elastic net 0.065 (0.014 – 0.287) 0.000 0.040 (0.008 – 0.198) 0.000
Denmark dataset Lasso 0.055 (0.007 – 0.453) 0.007 0.044 (0.005 – 0.396) 0.005
Ridge 0.112 (0.024 – 0.519) 0.005 0.080 (0.014 – 0.467) 0.005
Elastic net 0.057 (0.007 – 0.464) 0.007 0.038 (0.004 – 0.389) 0.005
Australian dataset Lasso 0.565 (0.396 – 0.805) 0.002 0.549 (0.384 – 0.784) 0.001
Ridge 0.447 (0.312 – 0.641) 0.000 0.454 (0.316 – 0.651) 0.000
Elastic net 0.523 (0.370 – 0.739) 0.000 0.529 (0.373 – 0.748) 0.000
USA dataset Lasso 0.105 (0.010 – 1.068) 0.056 0.104 (0.010 – 1.052) 0.055
Ridge 0.130 (0.013 – 1.294) 0.082 0.129 (0.013 – 1.283) 0.081
Elastic net 0.120 (0. 012 – 1.195) 0.071 0. 122 (0. 012 – 1.214) 0. 072
Norway dataset Lasso — — — —
Ridge — — — —
Elastic net 0.536 (0.300 – 0.957) 0.035 0.569 (0.318 – 1.018) 0.057
This table shows the comparison with the LASSO, Ridge regression and Elastic Net methods for 19 gene signatures based on our dataset and other external datasets
from different countries. Univariate and multivariate Cox’s proportional hazard model analysis of prognostic factor (prognostic index or risk score) for overall survival
[Relevant location: Page 16]
Table 5 The probe ID, gene symbols and expression of the 19 genes in the poor survival group compared to the good survival group
Probe ID Gene symbol Gene name Expression in poor survival group
(Up-regulated/Down-regulated)
7000692 MRPL52 mitochondrial ribosomal protein L52 Down-regulated
5700373 TRIP13 thyroid hormone receptor interactor 13 Down-regulated
2690324 ITPRIP inositol 1,4,5-triphosphate receptor interacting protein Up-regulated
7000184 SLC38A9 solute carrier family 38, member 9 Down-regulated
5420070 FRMD6 FERM domain containing 6 Up-regulated
4230739 SORCS2 sortilin-related VPS10 domain containing receptor 2 Up-regulated
6040070 ELTDI EGF, latrophilin and seven transmembrane domain containing 1 Up-regulated
1190176 NOTCH2 Notch homolog 2 Up-regulated
2570196 CPXCR1 CPX chromosome region, candidate 1 Down-regulated
840367 OR10H5 olfactory receptor, family 10, subfamily H, member 5 Down-regulated
3450575 PDC phosducin Down-regulated
2710564 DUOX2 dual oxidase 2 Up-regulated
4560474 GFRA4 GDNF family receptor alpha 4 Down-regulated
5690064 LASS6 LAG1 homolog, ceramide synthase 6 Down-regulated
3780725 OSBPL9 oxysterol binding protein-like 9 Down-regulated
5090025 C12orf66 chromosome 12 open reading frame 66 Down-regulated
5870121 SPG7 spastic paraplegia 7 (pure and complicated autosomal recessive) Up-regulated
620398 DUSP21 dual specificity phosphatase 21 Down-regulated
540411 BRCA1 breast cancer 1, early onset Down-regulated
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inadequate sampling of lymph nodes as a risk factor in the
conventional clinico-pathologic approach to determine
staging could be disregarded [16, 28].
From our findings, some of the signature genes play
roles in cell differentiation and amino acid transport as
well as coding for phosphoproteins, receptors and
membrane-associated proteins. We validated and con-
firmed six out of the 19 genes using RT-PCR. One of
these is the EGF latrophilin and seven transmembrane
domain-containing protein 1 (ELTD1) gene. A previous
in vivo study found that a high expression (~3 fold
increase, p <0.001) of this gene was associated with high
grade gliomas and low survival rate [29]. In our study,
ELTDI was consistently up-regulated in the group of
CRC patients with poor survival. The ELTDI gene is a
member of the secretin family of G protein–coupled
peptide hormone receptors and belongs to the EGF-7
transmembrane subfamily. The EGF family plays import-
ant roles in cell division, apoptosis, differentiation and
migration [30]. Wallgard et al. [31] reported that ELDT1
is associated with microvasculature expression of endo-
thelial cell-specific in vivo for tumor progression.
The second validated gene, thyroid hormone receptor
interactor 13 (TRIP13), encodes a protein that cooper-
ates with thyroid hormone receptors. High expression of
TRIP13 gene was reported to be associated with poor
prognosis in breast cancer [32]. One of the gene in this
panel was the sortilin-related VPS10 domain containing
receptor 2 (SORCS2) which found to be up-regulated in
the group with poor survival compared to those with
good survival. This gene is normally highly expressed in the
central nervous system during development [33, 34]. In
contrast, this gene was documented to be down-regulated
in the stromal cells of breast cancer and associated with
poor outcome [35, 36]. Another one of the genes in the
panel i.e., Notch homolog 2 (NOTCH2) has been widely
reported to be linked with survival. NOTCH2 is a receptor
for membrane bound ligands and has roles in vascular, renal
and hepatic development [37, 38]. The NOTCH2 gene was
also reported to be an independent prognostic predictor of
CRC [39]. A high expression of NOTCH2 might predict
good survival in CRC with a median survival of 45 months
[39]. We noted an opposite effect of this gene in our current
study. This is probably due to the heterogeneity of tissue
samples with different stages of tumor tissues between the
respective studies. Less information are available for six of
the genes in the panel in relation to cancer namely the
ITPRIP, FRMD6, CPXCR1, SLC38A9, MRPL52 and GFRA4.
We showed that the performance of the 19-gene
signature was reliable and also reproducible. This was
evident through the use of four external validation series
from other countries with different population settings.
A similar study used information from other studies to
validate the performance of their 5-gene panel [40]. Our
study results show the robustness of the gene panel
whereby the test successfully differentiate patients into
groups with high and low risk of recurrence in the train-
ing, testing and also the external validation datasets.
Conclusions
We have shown that our 19-gene signature is able to classify
CRC patients into prognostic groups according to their risk
scores. Patient who will be assigned into the high risk group
could have a proper treatment plan, relevant chemotherapy
dosage and effective medication strategy in order to increase
the survival rate at the same time reduce the invasiveness of
cancer cells. While for patients who were classified as the
low risk group could avoid or received lower doses of
adjuvant chemotherapy. Further validation tests are still
required using larger number of samples. Future prospective
clinical trials could also be conducted using this classifier to
randomize treatment groups and explore further the sensi-
tivity and specificity of this 19-gene signature.
Fig. 4 Validation of detected genes using qPCR. The normalized gene expression ratio for six genes including FRMD6, ELTD1, ITPRIP, MRPL52, TRIP13
and SLC38A9 which was determined using qPCR (p < 0.05). (*) represents the significant genes
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Additional file
Additional file 1: a) Detection of outliers. b) Summary of permutation
analysis. a) Detection of outliers. Histogram of microarray data showing
the presence of outliers after detection by using the beta weight
function. Samples with weight index < 0.2 were considered as outliers.
b) Summary of the permutation analysis for 78 CRC samples to identify
differentially expressed genes. One hundred training and test set were
generated and further analyzed using 3 statistical methods: SAM, LIMMA
and t-test to calculate the p-value for each gene. (DOCX 452 kb)
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